Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group/2009-02 study
European Journal of Cancer2016Vol. 58, pp. 122–129
Citations Over TimeTop 17% of 2016 papers
Antonio Llombart‐Cussac, Manuel Ramos, E. Dalmau, José Á. García-Sáenz, Xavier González, Laura Murillo, Lourdes Calvo, Serafín Morales, Vicente Carañana, Ana González, L.A. Fernández-Morales, Fernando Moreno, Ma Isabel Casas, Ma del Mar Angulo, M. Camara, Ana I. Garcia-Mace, Eva Carrasco, Carlos Jara-Sánchez
Related Papers
- → Aprepitant Has Mixed Effects on Nausea and Reduces Other Symptoms in Patients With Gastroparesis and Related Disorders(2017)142 cited
- → Aprepitant for the management of nausea with inpatient IV dihydroergotamine(2016)14 cited
- → Aprepitant in the Prevention of Vomiting Induced by Moderately and Highly Emetogenic Chemotherapy(2015)8 cited
- → Use of Oral Aprepitant for the Management of Nausea with Inpatient Intravenous Dihydroergotamine (DHE) Use (S40.006)(2013)
- Aprepitant for treatment of refractory vomiting in a case of brain abscess(2017)